U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C99H140N20O17
Molecular Weight 1882.2947
Optical Activity UNSPECIFIED
Defined Stereocenters 14 / 14
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VALINEGRAMICIDIN A

SMILES

CC(C)C[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=C3C=CC=C4)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC7=CNC8=C7C=CC=C8)C(=O)NCCO

InChI

InChIKey=ZWCXYZRRTRDGQE-LUPIJMBPSA-N
InChI=1S/C99H140N20O17/c1-51(2)37-73(109-86(123)59(17)107-81(122)49-105-96(133)82(55(9)10)106-50-121)89(126)108-60(18)87(124)117-84(57(13)14)98(135)119-85(58(15)16)99(136)118-83(56(11)12)97(134)116-80(44-64-48-104-72-34-26-22-30-68(64)72)95(132)112-76(40-54(7)8)92(129)115-79(43-63-47-103-71-33-25-21-29-67(63)71)94(131)111-75(39-53(5)6)91(128)114-78(42-62-46-102-70-32-24-20-28-66(62)70)93(130)110-74(38-52(3)4)90(127)113-77(88(125)100-35-36-120)41-61-45-101-69-31-23-19-27-65(61)69/h19-34,45-48,50-60,73-80,82-85,101-104,120H,35-44,49H2,1-18H3,(H,100,125)(H,105,133)(H,106,121)(H,107,122)(H,108,126)(H,109,123)(H,110,130)(H,111,131)(H,112,132)(H,113,127)(H,114,128)(H,115,129)(H,116,134)(H,117,124)(H,118,136)(H,119,135)/t59-,60-,73+,74+,75+,76+,77-,78-,79-,80-,82-,83+,84+,85-/m0/s1

HIDE SMILES / InChI

Molecular Formula C99H140N20O17
Molecular Weight 1882.2947
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 14 / 14
E/Z Centers 9
Optical Activity UNSPECIFIED

Linear gramicidin is a hydrophobic antibiotic polypeptide composed of 15 hydrophobic amino acids in D- and L-alternate conformers with the following sequence: formyl-L-X-gly-L-ala-D-leu-L-ala-D-val-L-val-D-val-L-trp-D-leu-Ltrp-D-leu-L-trp-D-leu-L-trp-ethanolamine where X represents either valine or isoleucine. Whether amino acid 11 is tryptophan, phenylalanine, or tyrosine, gramicidins are called A, B, or C, respectively. A mixture of three pairs of antibacterial substances (Gramicidin A, B, and C) is also called Gramicidin D and is produced by the growth of Bacillus brevis Dubos (Fam. Bacillaceae). Gramicidin is bactericidal for a variety of gram-positive organisms. It increases the permeability of the bacterial cell membrane to inorganic cations by forming a network of channels through the normal lipid bilayer of the membrane. Gramicidin is used in the combination with neomycin sulfate and polymyxin B sulfate (NEOSPORIN®) for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
NEOSPORIN

Approved Use

NEOSPORIN Ophthalmic Solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis, and keratoconjunctivitis, blepharitis, and blepharoconjunctivitis.

Launch Date

1955
Curative
NEOSPORIN

Approved Use

NEOSPORIN Ophthalmic Solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis, and keratoconjunctivitis, blepharitis, and blepharoconjunctivitis.

Launch Date

1955
Curative
NEOSPORIN

Approved Use

NEOSPORIN Ophthalmic Solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis, and keratoconjunctivitis, blepharitis, and blepharoconjunctivitis.

Launch Date

1955
Curative
NEOSPORIN

Approved Use

NEOSPORIN Ophthalmic Solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis, and keratoconjunctivitis, blepharitis, and blepharoconjunctivitis.

Launch Date

1955
Curative
NEOSPORIN

Approved Use

NEOSPORIN Ophthalmic Solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis, and keratoconjunctivitis, blepharitis, and blepharoconjunctivitis.

Launch Date

1955
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Instill one or two drops of NEOSPORIN® into the affected eye every 4 hours for 7 to 10 days. In severe infections, dosage may be increased to as much as two drops every hour.
Route of Administration: Topical
In Vitro Use Guide
The K+ transport in erythrocytes induced by gramicidin A or valinomycin is a first-order reaction. The activation energy of the induced transport is low and amounts to 6 and 10 kcal/mole, respectively. The indirect method for calculation of the driving force of diffusion, c, is given; in pig erythrocytes, the c value for gramicidin A is 21.7, and for valinomycin 35.4 mM-KCl. The gramicidin A-induced transport corresponds to that of a single gramicidin channel, and not to the multichannel transport observed in the model systems.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:13:09 GMT 2023
Edited
by admin
on Fri Dec 15 16:13:09 GMT 2023
Record UNII
93AG3Q5T2V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VALINEGRAMICIDIN A
Common Name English
1-L-VALINEGRAMICIDIN A
Common Name English
L-TRYPTOPHANAMIDE, N-FORMYL-L-VALYLGLYCYL-L-ALANYL-D-LEUCYL-L-ALANYL-D-VALYL-L-VALYL-D-VALYL-L-TRYPTOPHYL-D-LEUCYL-L-TRYPTOPHYL-D-LEUCYL-L-TRYPTOPHYL-D-LEUCYL-N-(2-HYDROXYETHYL)-
Systematic Name English
GRAMICIDIN A, 1-L-VALINE-
Common Name English
Code System Code Type Description
CAS
4419-81-2
Created by admin on Fri Dec 15 16:13:09 GMT 2023 , Edited by admin on Fri Dec 15 16:13:09 GMT 2023
PRIMARY
EPA CompTox
DTXSID80891352
Created by admin on Fri Dec 15 16:13:09 GMT 2023 , Edited by admin on Fri Dec 15 16:13:09 GMT 2023
PRIMARY
PUBCHEM
16132269
Created by admin on Fri Dec 15 16:13:09 GMT 2023 , Edited by admin on Fri Dec 15 16:13:09 GMT 2023
PRIMARY
FDA UNII
93AG3Q5T2V
Created by admin on Fri Dec 15 16:13:09 GMT 2023 , Edited by admin on Fri Dec 15 16:13:09 GMT 2023
PRIMARY